Nordson's 2026 Outlook: Recurring Revenue Base Drives Sustained Long-Term Profitability

Picture a specialized assembly line where a tiny, high-precision nozzle dispenses just enough adhesive to seal a delicate medical device or secure a chip inside a smartphone. This is the world of Nordson (NASDAQ:NDSN), a company that engineers the hardware controlling how liquids, polymers, and biomaterials are applied across everything from consumer electronics to advanced medical technology. The stock, which trades at $309.86 as of Sept. 15, 2026, has gained 37% over the past year, reflecting investor confidence in its role as a quiet, essential backbone of modern manufacturing.

Our proprietary Hidden Gems scoring system assigns Nordson an overall Superscore of 76 out of 100, placing it in the Above Average category. The Superscore is an AI-powered score that evaluates a company's overall strength by combining financial performance, product market position, technological capabilities, leadership quality, and relative valuation. It represents the unification of all our scores into a single score for public companies, with five rating bands: Exceptional (90-100), Strong (75-89), Above Average (60-74), Average (40-59), and Cautious (0-39).

A 76 places Nordson in the Top ~22% of all companies we score, ahead of roughly 78 out of every 100 companies. This score serves as one data-driven signal for your research, and this piece pairs the reasons for this strength with the constraints that keep it from ranking higher, so you can weigh both sides.

Why NDSN Has a 76 Superscore

• Essential precision hardware: The company dominates niche markets for fluid dispensing, a critical bottleneck in semiconductor packaging that forces manufacturers to rely on its proprietary equipment.
• Recurring revenue base: High-margin consumables such as nozzles and filters account for 56% of revenue, ensuring customers pay for parts long after the original system is installed.
• Disciplined capital allocation: Management successfully integrates bolt-on acquisitions such as CapstanAG while maintaining a strong balance sheet, demonstrating the ability to scale revenue through targeted, high-return moves.
• Operational margin strength: A relentless focus on lean manufacturing processes enables the company to maintain a consistent EBITDA margin of 32%, demonstrating significant operating leverage.

Why Is NDSN's Superscore Not Higher?

• Single-digit revenue growth: Revenue has grown at a compound annual rate of 5% over the past decade, reaching nearly $3 billion on a trailing-12-month basis. Consistent acquisition-driven expansion masks a lack of breakout organic momentum in its core segments.
• Elevated valuation multiple: The stock trades at a trailing P/E of 31.3x, which leaves little margin for error if industrial demand cools or integration challenges emerge from its recent acquisition cycle.
• Cyclical industrial exposure: Despite its medical pivot, large portions of the business remain sensitive to broader industrial cycles, creating volatility that can dampen sentiment when capital spending slows.
• Integration complexity: The strategy of buying growth via M&A increases long-term debt and operational complexity, requiring management to execute perfectly to justify the premium paid for these assets.

Hidden Gems Database Scores at a Glance

Is NDSN Right For Your Portfolio?

This stock warrants a closer look if...

• You seek a compounder within industrial stocks that relies on recurring, high-margin parts sales to sustain long-term profitability.
• You appreciate a disciplined management team that pairs steady R&D spending with opportunistic acquisitions to expand its technological moat.

You may want to keep researching before buying if...

• You are concerned by the lack of significant top-line organic growth over the past four fiscal years.
• You find the current valuation multiple of 31 times trailing earnings too high for a business with moderate organic growth prospects.

The Superscore is one data-driven signal worth investigating; please weigh it against your own financial goals, risk tolerance, and independent research before acting.

My 5-year prediction for NDSN stock

The stock could marginally outperform the market over the next five years. The company's backlog has been accelerating, up 35% year over year last quarter. This provides high visibility to future growth.

Over half of the company's portfolio is positioned in attractive and growing markets such as semiconductors, electronics, and medical devices. Moreover, the majority of its revenue is recurring, which is why investors are willing to pay such a high premium for the shares.

However, there's also the chance the stock underperforms in the next five years. This could happen if there is severe macroeconomic pressure, including inflationary headwinds in freight costs and commodity prices. These headwinds could pressure margins, limiting the company's ability to grow earnings at double-digit rates.

Still, assuming Nordson meets analysts' expectations for earnings growth at an annualized rate of 13% over the coming years, the stock could be a good investment. Sound capital allocation in the right opportunities, focusing on profitable niche markets, and expanding margins could lead the stock to outperform over the next five years.

The Hidden Gems Superscore reflects The Motley Fool's proprietary AI-driven evaluation of a company across product, financial, leadership, and valuation pillars as of the article date and may change over time. Performance figures are point-in-time. Past performance does not guarantee future results.

John Ballard has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.